Abstract
The thyroid hormone triiodothyronine (T3) has been used both to augment and accelerate the clinical effects of antidepressants, particularly the tricyclics. More recent work indicates that it may have similar actions with regard to the SSRIs. Two main mechanisms have been put forward to explain its antidepressant actions, (a) an action at the nuclear level involving stimulation of gene transcription, (b) an action at the cell membrane level involving potentiation of neurotransmission. In particular, there is considerable evidence for potentiation by T3 of the actions of the neurotransmitter 5- HT or serotonin. This evidence, which is mainly based on in vivo microdialysis studies, is reviewed, and evidence based on human and animal neuroendocrine studies considered. The effects of T3, alone and together with the SSRI fluoxetine, on mRNA levels for the 5-HT1A and 5-HT1B autoreceptors, which mediate serotonergic neurotransmission by feedback actions at the levels of cell firing(somatodendritic 5-HT1A autoreceptors) and neurotransmitter release (nerve terminal 5- HT1B autoreceptors) were also determined. Administration of a combination of fluoxetine and T3 induced reductions in the transcription of these autoreceptors, which may explain the clinical potentiating effects of this combination, and thus link the nuclear and neurotransmitter hypotheses of T3 action.
Keywords: Triiodothyronine, serotonin, depression, antidepressant, microdiaysis, mRNA, fluoxetine, autoreceptor
Current Drug Targets
Title: Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone
Volume: 7 Issue: 2
Author(s): Tsuri Lifschytz, Ronen Segman, Galit Shalom, Bernard Lerer, Eitan Gur, Tanya Golzer and Michael E. Newman
Affiliation:
Keywords: Triiodothyronine, serotonin, depression, antidepressant, microdiaysis, mRNA, fluoxetine, autoreceptor
Abstract: The thyroid hormone triiodothyronine (T3) has been used both to augment and accelerate the clinical effects of antidepressants, particularly the tricyclics. More recent work indicates that it may have similar actions with regard to the SSRIs. Two main mechanisms have been put forward to explain its antidepressant actions, (a) an action at the nuclear level involving stimulation of gene transcription, (b) an action at the cell membrane level involving potentiation of neurotransmission. In particular, there is considerable evidence for potentiation by T3 of the actions of the neurotransmitter 5- HT or serotonin. This evidence, which is mainly based on in vivo microdialysis studies, is reviewed, and evidence based on human and animal neuroendocrine studies considered. The effects of T3, alone and together with the SSRI fluoxetine, on mRNA levels for the 5-HT1A and 5-HT1B autoreceptors, which mediate serotonergic neurotransmission by feedback actions at the levels of cell firing(somatodendritic 5-HT1A autoreceptors) and neurotransmitter release (nerve terminal 5- HT1B autoreceptors) were also determined. Administration of a combination of fluoxetine and T3 induced reductions in the transcription of these autoreceptors, which may explain the clinical potentiating effects of this combination, and thus link the nuclear and neurotransmitter hypotheses of T3 action.
Export Options
About this article
Cite this article as:
Lifschytz Tsuri, Segman Ronen, Shalom Galit, Lerer Bernard, Gur Eitan, Golzer Tanya and Newman E. Michael, Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone, Current Drug Targets 2006; 7 (2) . https://dx.doi.org/10.2174/138945006775515482
DOI https://dx.doi.org/10.2174/138945006775515482 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Endothelial Dysfunction in Sepsis
Current Vascular Pharmacology An Update of the Classical and Novel Methods Used for Measuring Fast Neurotransmitters During Normal and Brain Altered Function
Current Neuropharmacology MicroRNAs as Regulators in Normal Hematopoietic and Leukemia Stem Cells: Current Concepts and Clinical Implications
Current Molecular Medicine The Insulin-sensitizing Role of the Fat Derived Hormone Adiponectin
Current Pharmaceutical Design Borderline Personality Disorder in Adolescents
Adolescent Psychiatry The Role of N-Methyl-D-Aspartate Receptor - Mediated Neurotransmission in Attention Deficit (Hyperactivity) Disorder (ADHD/ADD)
Current Psychopharmacology A Hydrazide Linker Strategy for Heterobivalent Compounds as Ortho- and Allosteric Ligands of Acetylcholine-Binding Proteins
Current Topics in Medicinal Chemistry Marijuana Use in Young Adults: What Do We Know?
Current Psychopharmacology Sigma-1 Receptors and Selective Serotonin Reuptake Inhibitors: Clinical Implications of their Relationship
Central Nervous System Agents in Medicinal Chemistry Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Current Pharmaceutical Design Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Neuroplasticity Regulation by Noradrenaline in Mammalian Brain
Current Neuropharmacology Adaptation to Traumatic Stress: Resilient Traits, Resources, and Trajectories of Outcomes
Current Psychiatry Reviews Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer’s disease
CNS & Neurological Disorders - Drug Targets Recent Progress on Antifungal Drug Development
Current Pharmaceutical Biotechnology Trigeminal Neuralgia: Basic and Clinical Aspects
Current Neuropharmacology Meet Our Editorial Board Member
Recent Patents on Biotechnology Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Computational Methods in Determination of Pharmacophore Models of 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>7</sub> Receptors
Mini-Reviews in Medicinal Chemistry